Safety and Efficacy of the AbsnowTM II Absorbable Atrial Septal Defect Closure System for Atrial … (NCT07529028) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Safety and Efficacy of the AbsnowTM II Absorbable Atrial Septal Defect Closure System for Atrial Septal Defect Closure Therapy
236 participantsStarted 2026-04
Plain-language summary
A prospective, multicenter, randomized controlled, non-inferiority clinical trial to evaluate the safety and efficacy of the AbsnowTM II absorbable atrial septal defect occluder system for atrial septal defect closure therapy. A parallel controlled comparison will be conducted using the Cera atrial septal defect occluder manufactured by the same company as the control device, to evaluate the safety and efficacy of the AbsnowTM II absorbable ASD occluder system in the treatment of ASD occlusion.
Who can participate
Age range3 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Aged≥3years, body weight≥10 kg, regardless of gender;
✓. Patients with secundum atrial septal defect (ASD) with left-to-right shunt and evidence of right ventricular volume overload (echocardiography indicating right ventricular enlargement);
✓. ASD diameter≥5 mm and\<26 mm;
✓. The distance from the ASD rim to the openings of the superior/inferior vena cava and pulmonary veins≥5mm, and the distance to the atrioventricular valve≥7mm;
✓. Patients who can understand the trial purpose, voluntarily participate and sign the informed consent form, and are willing to cooperate with follow-up completion.
Exclusion criteria
✕. Primum, sinus venosus, and unroofed coronary sinus types of atrial septal defect (ASD);
✕. Patients with ASD diameter≥26 mm;
✕. Combined with other structural heart diseases requiring treatment besides ASD;
✕. Complicated with severe pulmonary hypertension or Eisenmenger syndrome;
✕. Patients who suffered from infectious diseases within 1 month before enrollment, including infective endocarditis, or those with uncontrolled infectious diseases;
✕. Patients who suffered from hemolysis, hemorrhagic diseases, unhealed peptic ulcer within 1 month before enrollment, or have any contraindications to aspirin therapy (except those who can take other antiplatelet drugs continuously for 6 months);
✕. Intracardiac thrombus detected by echocardiography (especially thrombus in the left atrium or left atrial appendage), or venous thrombosis at the catheter insertion site;
✕. Patients allergic to the materials of the investigational medical device;